Proost JH - Search Results

1

Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.

Prakash J, van Loenen-Weemaes AM, Haas M, Proost JH, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Prakash J, et al. Among authors: proost jh. Drug Metab Dispos. 2005 May;33(5):683-8. doi: 10.1124/dmd.104.002808. Epub 2005 Jan 26. Drug Metab Dispos. 2005. PMID: 15673598

2

Renal targeting of captopril using subcutaneous administration of captopril-lysozyme conjugate.

Prakash J, Kok RJ, van Loenen-Weemaes A, Haas M, Proost JH, Meijer DK, Moolenaar F. Prakash J, et al. Among authors: proost jh. J Control Release. 2005 Jan 3;101(1-3):350-1. J Control Release. 2005. PMID: 15765569 No abstract available.

3

Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis.

Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Këri G, Meijer DK, Poelstra K, Kok RJ. Prakash J, et al. Among authors: proost jh. J Pharmacol Exp Ther. 2006 Oct;319(1):8-19. doi: 10.1124/jpet.106.106054. Epub 2006 Jun 28. J Pharmacol Exp Ther. 2006. PMID: 16807361

4

Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats.

Greupink R, Reker-Smit C, Proost JH, van Loenen Weemaes AM, de Hooge M, Poelstra K, Beljaars L. Greupink R, et al. Among authors: proost jh. Biochem Pharmacol. 2007 May 1;73(9):1455-62. doi: 10.1016/j.bcp.2006.12.017. Epub 2006 Dec 15. Biochem Pharmacol. 2007. PMID: 17239825

5

Pharmacokinetics and whole body distribution of elastase derived angiostatin (K1-3) in rats.

Molema G, van Veen-Hof I, van Loenen-Weemaes AM, Proost JH, de Leij LF, Meijer DK. Molema G, et al. Among authors: proost jh. Int J Cancer. 2001 Jan 1;91(1):1-7. doi: 10.1002/1097-0215(20010101)91:1<1::aid-ijc1001>3.0.co;2-5. Int J Cancer. 2001. PMID: 11149408

6

Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.

Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G. Schraa AJ, et al. Among authors: proost jh. Int J Cancer. 2002 Dec 10;102(5):469-75. doi: 10.1002/ijc.10727. Int J Cancer. 2002. PMID: 12432548

7

Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations.

Proost JH, Beljaars L, Olinga P, Swart PJ, Kuipers ME, Reker-Smit C, Groothuis GM, Meijer DK. Proost JH, et al. Eur J Pharm Sci. 2006 Feb;27(2-3):123-32. doi: 10.1016/j.ejps.2005.08.014. Epub 2005 Oct 10. Eur J Pharm Sci. 2006. PMID: 16219448

8

PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.

Bansal R, Post E, Proost JH, de Jager-Krikken A, Poelstra K, Prakash J. Bansal R, et al. Among authors: proost jh. J Control Release. 2011 Sep 25;154(3):233-40. doi: 10.1016/j.jconrel.2011.05.027. Epub 2011 Jun 12. J Control Release. 2011. PMID: 21664391

9

MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Proost JH, Meijer DK. Proost JH, et al. Comput Biol Med. 1992 May;22(3):155-63. doi: 10.1016/0010-4825(92)90011-b. Comput Biol Med. 1992. PMID: 1617949

10

[Basic understanding of pharmacokinetics that every doctor should know].

Proost JH, Moolenaar F, de Graeff PA. Proost JH, et al. Ned Tijdschr Geneeskd. 2009 Jan 24;153(4):148-52. Ned Tijdschr Geneeskd. 2009. PMID: 19348139 Review. Dutch. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters